PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17954368-2 2007 We evaluated whether quinapril unmasks angiotensin II-dependent sympathetic activity on amlodipine. Quinapril 21-30 angiotensinogen Homo sapiens 39-53 15353612-12 2005 In order to confirm that the action of quinapril occurred predominantly through suppression of angiotensin II, parallel experiments with the angiotensin receptor antagonist candesartan cilexetil demonstrated that this agent also inhibited disease activity in CIA. Quinapril 39-48 angiotensinogen Homo sapiens 95-109 16206603-0 2005 [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)]. Quinapril 23-32 angiotensinogen Homo sapiens 76-90 11849656-6 2002 According to quinapril treatment, the AGT T homozygotes significantly showed a beneficial effect of quinapril on MLD (P=0.013) and late lumen loss (P=0.013). Quinapril 13-22 angiotensinogen Homo sapiens 38-41 15526248-6 2004 In the quinapril group, the mean maximal vasoconstriction to Ang II was similar between DD- and ID/II-genotype (59.6+/-9.19% [n=8] vs. 57.7+/-4.07% [n=35]; p=0.85). Quinapril 7-16 angiotensinogen Homo sapiens 61-67 15526248-7 2004 CONCLUSIONS: DD-genotype patients showed decreased vascular responses to Ang II but treatment with quinapril completely restored the decreased vascular response in DD-genotype patients to the same level as II/ID-genotype patients, while no effect of quinapril was demonstrated in the II/ID-genotype patients. Quinapril 99-108 angiotensinogen Homo sapiens 73-79 11849656-6 2002 According to quinapril treatment, the AGT T homozygotes significantly showed a beneficial effect of quinapril on MLD (P=0.013) and late lumen loss (P=0.013). Quinapril 100-109 angiotensinogen Homo sapiens 38-41 11849656-9 2002 In conclusion, the AGT T homozygotes might benefit from effects of quinapril on preventing restenosis after PCI. Quinapril 67-76 angiotensinogen Homo sapiens 19-22 1575171-6 1992 The blood pressure reduction in patients with mild hypertension receiving long-term quinapril therapy may be more closely related to prolonged angiotensin-converting enzyme inhibition or to an effect on tissue angiotensin II concentration than to the plasma half-life. Quinapril 84-93 angiotensinogen Homo sapiens 210-224 9049577-3 1997 This study assesses the in vivo effect of single oral doses of quinapril and enalapril, in attenuating the vasoconstrictive action of angiotensin I (AI) (which we have previously shown depends on its conversion to angiotensin II (AII) by vascular ACE) in the forearm resistance vessels of man. Quinapril 63-72 angiotensinogen Homo sapiens 134-147 9049577-3 1997 This study assesses the in vivo effect of single oral doses of quinapril and enalapril, in attenuating the vasoconstrictive action of angiotensin I (AI) (which we have previously shown depends on its conversion to angiotensin II (AII) by vascular ACE) in the forearm resistance vessels of man. Quinapril 63-72 angiotensinogen Homo sapiens 214-228 9049577-3 1997 This study assesses the in vivo effect of single oral doses of quinapril and enalapril, in attenuating the vasoconstrictive action of angiotensin I (AI) (which we have previously shown depends on its conversion to angiotensin II (AII) by vascular ACE) in the forearm resistance vessels of man. Quinapril 63-72 angiotensinogen Homo sapiens 230-233 9037848-3 1996 Because quinapril is an angiotensin-converting enzyme inhibitor and could result in a decrease of angiotensin-II, Quinapril was used to treat patients with mild or moderate hypertension in order to observe the change of plasma serotonin. Quinapril 8-17 angiotensinogen Homo sapiens 98-112 2539762-4 1989 In addition, plasma renin activity increased and aldosterone and angiotensin II concentrations decreased following single or multiple doses of quinapril. Quinapril 143-152 angiotensinogen Homo sapiens 65-79